Wednesday, August 6, 2025 8/6/2025

Quantitative analysis of heparan sulfate using 13C-labeled standards

Award Number: R43GM142304
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/15/2021
PERIOD OF PERFORMANCE END DATE: 09/16/2022

Group Awards By:

View Award Description

Quantitative analysis of heparan sulfate using 13C-labeled standards - This SBIR phase I proposal is aimed at developing to develop a LC-MS/MS based method to analyze heparan sulfate in the sub-nanogram range. Heparan sulfate is a highly sulfated polysaccharide displaying a wide range of biological functions. There is a strong demand for a quantitative and sensitive method to analyze heparan sulfate. In this proposal, we propose to achieve the quantitation of heparan sulfate using the disaccharide analysis. To this end, heparan sulfate is depolymerized into eight disaccharides by heparin lyases. The composition analysis of the resultant disaccharides is accomplished by a LC-MS/MS method. The crucial innovation in our proposed method is to add “absolute quantitation” capability using eight 13C-labeled disaccharide calibrants and one 13C-labeled polysaccharide calibrant. Aim 1 is designed to demonstrate the ability to quantitative compositional analysis of heparan sulfate from mouse tissues and plasma. In phase I studies, we will focus on analyzing the HS from plasma, lung, liver, and kidney from healthy mice and burn injury mice. Aim 2 is aimed to conduct quantitative analysis of heparan sulfate from a single histological slide. The sensitivity of the LC-MS/MS method will be improved. In the phase I studies, we will analyze the heparan sulfate from histological slides from lung, liver, and kidney from healthy and burn injury mice. In the phase II studies, we plan to expand the analysis of heparan sulfate to all mouse tissues from healthy mice and four disease mice. We also plan to conduct the analysis from clinical samples from burn patients and sepsis patients in phase II studies. The success of this project will provide a method to analyze heparan sulfate with sensitivity and accuracy for biologists and will be a major break-through in glycobiology research.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2023 ( Subtotal = -$2 )
2023	2021	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST	RALEIGH	NC	27606	WAKE	USA	Biomedical Research and Research Training	000	1	7/20/2023	NEW	-$2
														Subtotal = -$2

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2021	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST STE 101	RALEIGH	NC	27606	WAKE	USA	Biomedical Research and Research Training	001	1	9/8/2022	NEW	$0
2022	2021	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST STE 101	RALEIGH	NC	27606	WAKE	USA	Biomedical Research and Research Training	000	1	11/9/2021	NEW	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $300,000 )
2021	2021	GLYCAN THERAPEUTICS CORPORATION	617 HUTTON ST STE 101	RALEIGH	NC	27606	WAKE	USA	Biomedical Research and Research Training	000	1	9/14/2021	NEW	$300,000
														Subtotal = $300,000

Grand Total All Awards = $299,998

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Quantitative analysis of heparan sulfate using 13C-labeled standards

Award Number: R43GM142304

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/15/2021

PERIOD OF PERFORMANCE END DATE: 09/16/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer